Hernández MM, Silva GÓG, Rangel AJM, Sánchez NMR

Language: Spanish
References: 18
Page: 7-12
PDF size: 308.45 Kb.

ABSTRACT

Introduction. Mexico ranks third in resistance to antimicrobials intended to treat tuberculosis. In this study, will describe the prevalence of Mycobacterium tuberculosis resistant to first-line drugs in the state of Guanajuato.
Methodology. A retrolective cross-sectional descriptive study was carried out in 1 194 samples from patients with suspected tuberculosis. The study includes data collected from patients with samples obtained by expectoration or bronchoalveolar aspirate. The samples were cultured, analyzed, and identified for M. tuberculosis using the lateral immunochromatographic test for the detection of the MPT64 antigen and by the characteristic colonial morphology of acid-fast bacilli (AFB) using Ziehl-Neelsen stain. Cultures positive for M. tuberculosis were analyzed by drug susceptibility tests (PFS) in the first instance to rifampicin and isoniazid, and later to pyrazinamide. Data were presented as prevalence of resistance to the different drugs.
Results. Of 1 194 clinical samples with suspected tuberculosis in the period from January 2021 to September 2022, 58 were positive to the M. tuberculosis complex test. The prevalence of resistance to rifampicin was 7%, that of isoniazid 9% and pyrazinamide 38%. Meanwhile, the prevalence of resistance to antibiotics in patients without prior treatment was 63% (10) and with prior treatment 25% (10).
Conclusion. The prevalence of M. tuberculosis resistant to pyrazinamide (38%) is higher than rifampicin (7%) and isoniazid (9%) in patients with tuberculosis in Guanajuato in the period January 2021 to September 2022.

REFERENCES

1. Xu, G., Liu, H., Jia, X., Wang, X. y Xu, P., “Mechanismsand detection methods of Mycobacterium tuberculosisrifampicin resistance: the phenomenon of drug resistanceis complex”, Tuberculosis, 2021, 128.

2. World Health Organization, “Global tuberculosis report2021”, Ginebra, who, 2021.

3. Organización Mundial de la Salud, “Tuberculosis 2021”.Consultados el 1 de junio de 2022. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/tuberculosis.

4. Tuberculosis | Secretaría de Salud | Gobierno | gob.mx,2016. Consultado el 1 de junio de 2022. Disponible en:https://www.gob.mx/salud/acciones-y-programas/tuberculosis.

5. Flores-Treviño, S., Rodríguez-Noriega, E., Garza-González,E., González-Díaz, E., Esparza-Ahumada, S., Escobedo-Sánchez, R. et al., “Clinical predictors of drug-resistanttuberculosis in Mexico”, plos One, 2019, 14 (8): 1-9.

6. Organización Panamericana de Salud-OrganizaciónMuncial de la Salud, “Tuberculosis”. Consultado el 1 dejunio de 2022. Disponible en: https://www.paho.org/es/temas/tuberculosis.

7. Caminero, J.A., Cayla, J.A., García-García, J.M., García-Pérez, F.J., Palacios, J.J. y Ruiz-Manzano, J., “Diagnósticoy tratamiento de la tuberculosis con resistenciaa fármacos”, Arch Bronconeumol, 2017, 53 (9): 501-509.

8. Castillo Rodal, A.I., “Tuberculosis, enfermedad antiguasin erradicarse”, Boletín unam-dgcs, 2022, 232. Consultadoel 1 de junio de 2022. Disponible en: https://www.dgcs.unam.mx/boletin/bdboletin/2022_232.html.

9. Zaw, M.T., Emran, N.A y Lin, Z., “Mutations inside rifampicin-resistance determining region of rpob geneassociated with rifampicin-resistance in Mycobacteriumtuberculosis”, J Infect Public Health, 2018, 11 (5): 605-610.

10. Lamont, E.A., Dillon, N.A. y Baughn, A.D., “The bewilderingantitubercular action of pyrazinamide”, MicrobiolMol Biol Rev, 2020, 84 (2): 1-15.

11. Gutiérrez-Aroca, J.B., Ruiz, P. y Casal, M., “Antimicrobialresistance in tuberculosis”, Rev Esp Quimioter, 2013, 26(4): 332-336.

12. López-Ávalos, G., González-Palomar, G., López-Rodríguez,M., Vázquez-Chacón, C.A., Mora-Aguilera, G.,González-Barrios, J.A. et al., “Genetic diversity of Mycobacteriumtuberculosis and transmission associatedwith first-line drug resistance: a first analysis in Jalisco,Mexico”, J Glob Antimicrob Resist, 2017, 11: 90-97.

13. Almaraz-Velasco, R., Munro-Rojas, D., Fuentes-Domínguez,J., Muñiz-Salazar, R., Ibarra-Estela, M., Guevara-Méndez, A. et al., “A first insight into the geneticdiversity of Mycobacterium tuberculosis in Veracruz,Mexico”, Int J Mycobacteriology, 2017, 6 (1): 14.

14. Flores-Treviño, S., Morfín-Otero, R., Rodríguez-Noriega,E., González-Díaz, E., Pérez-Gómez, H.R., Bocanegra-García, V. et al., “Genetic diversity of Mycobacteriumtuberculosis from Guadalajara, Mexico and identificationof a rare multidrug resistant beijing genotype”, R.Manganelli, ed., plos One, 2015, 10 (2): e0118095.

15. Che, Y., Bo, D., Lin, X., Chen, T., He, T. y Lin, Y., “Phenotypicand molecular characterization of pyrazinamideresistance among multidrug-resistant Mycobacteriumtuberculosis isolates in Ningbo, China”, bmc Infect Dis,2021, 21 (1): 1-8.

16. Ahmad, F., Rani, A., Alam, A., Zarin, S., Pandey, S., Singh,H. et al., “Macrophage: a cell with many faces and functionsin tuberculosis”, Front Immunol, 2022, 13: 1-18.

17. Sánchez-Pérez, J.H., “Tuberculosis in Mexico in timesof covid-19: some reflections”, Enf Emerg, 2021, 20 (3):160-165.

18. Migliori, G.B., Casco, N., Jorge, A.L., Palmero, D.J.,Alffenaar, J.W., Denholm, J. et al., “Tuberculosis andcovid-19 co-infection: description of the global cohort”,Eur Respir J, 2022, 59 (3): 2102538.